New Post-Market Surveillance (PMS) regulations have taken effect across Great Britain, requiring medical device manufacturers to proactively monitor the safety and performance of their products once on the market.
Similar Posts
Policy paper: Rare therapies and UK regulatory considerations
A paper outlining MHRA’s intentions to make it quicker and easier to get rare disease therapies tested, manufactured and approved in the UK.
Decision: Marketing authorisations granted in 2025
Marketing authorisations granted in 2025.
Decision: Human and veterinary medicines: register of licensed manufacturing sites
The MHRA register of licensed manufacturing sites: manufacturer specials – human (MS) and manufacturer specials authorisation – veterinary (MANSA) only.
Isotretinoin prescribing requirements updated with revised risk-minimisation measures
The updated safety measures will strengthen the MHRA’s ability to monitor safe prescribing while supporting patient access to treatment across all age groups.
Guidance: Medical devices: examples of reportable incidents
Examples of what manufacturers must report to the MHRA under the medical device vigilance system when incidents involving their devices occur in the UK.
MHRA smashes major illicit weight loss medicine production facility in record seizure
MHRA strikes massive blow to organised criminal gang in world’s biggest illegal weight loss jabs raid.